Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Generic Biologics: 505(b)(2) Route Still Open, But Scientific Issues Unresolved

Executive Summary

FDA is declining to rule out the possibility that the Sec. 505(b)(2) process could be used to allow expedited approval of follow-on biologic projects

You may also be interested in...



Omnitrope Lawsuit Could Further Delay FDA “Follow-On” Biologics Guidance

Sandoz' lawsuit against FDA over the human growth hormone product Omnitrope could further complicate the agency's efforts to define a potential approval route for "follow-on" biologics

Omnitrope Lawsuit Could Further Delay FDA “Follow-On” Biologics Guidance

Sandoz' lawsuit against FDA over the human growth hormone product Omnitrope could further complicate the agency's efforts to define a potential approval route for "follow-on" biologics

Follow-On Growth Hormone Has Precedent, Sandoz Says In Response To Pfizer

FDA's approval of Novo Nordisk's GlucaGen demonstrates that the agency has the legal authority to approve a follow-on version of human growth hormone, Sandoz maintains

Related Content

UsernamePublicRestriction

Register

ID004339

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel